Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isola...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Dillard, Pierre, Casey, Nicholas, Pollmann, Sylvie, Vernhoff, Patrik, Gaudernack, Gustav, Kvalheim, Gunnar, Wälchli, Sébastien, Inderberg, Else Marit
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2021
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8216182/
https://ncbi.nlm.nih.gov/pubmed/34235003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1936757
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items